Techfields Pharma Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Novel High Penetration Drugs and Their Compositions Thereof for Treatment of Parkinson Diseases (US 11,685,739) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for High Penetration Prodrug Compositions and Pharmaceutical Compoisiton Thereof for Treatment of Pulmonary Conditions (US 11,813,256) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for High Penetration Prodrug Compositions and Pharmaceutical Composition Thereof for Treatment of Pulmonary Conditions (US 11,857,545) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
- 3 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,786,497 | High penetration prodrug compositions of retinoids and retinoids-related compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,371,284 | Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 9,193,672 | High penetration prodrug compositions of retinoids and retinoid-related compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,969,751 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 11,485,744 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,376,381 | High penetration prodrug compositions of peptides and peptide-related compounds In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 11,541,029 | High Penetration Compositions and Their Applications In force · High confidence | In force | High confidence | |
| US 11,685,739 | Novel High Penetration Drugs and Their Compositions Thereof for Treatment of Parkinson Diseases In force · Medium confidence | In force | Medium confidence | |
| US 11,857,545 | High Penetration Prodrug Compositions and Pharmaceutical Composition Thereof for Treatment of Pulmonary Conditions In force · Medium confidence | In force | Medium confidence | |
| US 11,813,256 | High Penetration Prodrug Compositions and Pharmaceutical Compoisiton Thereof for Treatment of Pulmonary Conditions In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 7 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 3 abandoned · 10 no status recorded